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antibodies
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The presence of rheumatoid factor (RF) or anti‑cyclic citrullinated peptide (anti‑CCP) autoantibodies 
contributes to the current rheumatoid arthritis (RA) classification criteria. These criteria involve 
stratification on antibody levels, which limits reproducibility, and underperform in the RA patients 
without RF and anti‑CCP. Here, we have explored if two anti‑acetylated peptide antibodies (AAPA), 
anti‑acetylated lysine (AcLys) and anti‑acetylated ornithine (AcOrn), could improve the performance 
of the current criteria. The analysis was done in 1062 prospectively‑followed early arthritis (EA) 
patients. The anti‑AcOrn were more informative than the anti‑AcLys, the conventional RA antibodies 
and the anti‑carbamylated protein antibodies. The anti‑AcOrn produced a classification that did not 
require antibody levels and showed improved specificity (77.6% vs. 72.6%, p = 0.003) and accuracy 
(79.0% vs. 75.8%, p = 0.002) over the current criteria. These improvements were obtained with a 
scoring system that values concordance between anti‑AcOrn, RF and anti‑CCP. No significant gain was 
obtained in sensitivity (80.2% vs. 78.8%, p = 0.25) or in improving the classification of the RA patients 
lacking RF and anti‑CCP, although the anti‑AcOrn ranked first among the analysed new antibodies. 
Therefore, the anti‑AcOrn antibodies could contribute to the improvement of RA classification criteria 
by exploiting antibody concordance.
The patients with rheumatoid arthritis (RA) should be distinguished from other forms of arthritis for research 
and clinical  management1,2. The prompt identification at the onset of arthritis is difficult to achieve because of the 
lack of discriminant symptoms or signs and the absence of diagnostic  tests1,3. This limitation has been addressed 
through the elaboration of classification criteria by the American College of Rheumatology (ACR) and the 
European League Against Rheumatism, which primary focus is to identify homogeneous groups of patients for 
 research2,4. The current criteria were developed in 2010 to avoid the delay associated with the previous criteria 
dating from 1987 to permit clinical trials early in the disease course. One of the novelties of the 2010 criteria 
has been a scoring system that gives a remarkable weight to the best-known RA specific autoantibodies, the 
rheumatoid factor (RF) and anti-cyclic citrullinated peptides (anti-CCP)  antibodies2. Specifically, the patients 
showing high levels of any of the two antibodies receive 3 points, whereas the positive patients without high levels 
receive 2 points. These scores are a large fraction of the 6 points required for RA  classification2. These and other 
changes in the 2010 EULAR/ACR criteria have achieved the intended objective of a much prompt  classification5,6. 
However, there is still room for  improvement5–12.
Two areas have been identified that could lead to improvements by incorporating new RA 
 autoantibodies5–7,13–15. The most evident would be if the new antibody could cover the need of a biomarker for 
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the 15–45% RA patients that lack RF and anti-CCP  antibodies7,13. The accuracy of the current classification crite-
ria for these “seronegative” patients is much lower than for the patients bearing RF or anti-CCP5–8,11,12. However, 
the new RA autoantibodies analysed so far have provided small gains in this area because of their concordance 
with RF and anti-CCP  antibodies16–18. It is unclear if this characteristic also applies to the anti-acetylated peptide 
antibodies (AAPA)18. These antibodies are remarkable in comparison with other new RA  autoantibodies18–23. 
Perhaps, they are only comparable in reproducibility and apparent diagnostic characteristics to the anti-carba-
mylated protein antibodies (anti-CarP)24–26, although the two are less sensitive for RA than RF and anti-CCP 
antibodies. The AAPA are assayed with a modification of the peptide from the mutated citrullinated vimentin 
(MCV) kit, in which citrulline is replaced by acetylated lysine (AcLys) or acetylated ornithine (AcOrn)18,19. The 
test shows low levels of cross-reactivity with anti-CCP and anti-CarP  antibodies18. In spite of these promising 
clues, the potential value of the AAPA for RA classification has not been fully assessed. The available data shows 
discrepancies regarding their sensitivity for the “seronegative” patients. On one side, the report where they 
were first described observed a 13% sensitivity in the anti-CCP negative  patients18. On the other, two meeting 
abstracts have reported > 40% sensitivity in the “seronegative” RA  patients20,21. These latter results indicate the 
need to determine if the AAPA could significantly fill the need of a biomarker for the “seronegative” patients.
An alternative area of improvement of the 2010 EULAR/ACR classification criteria will aim to improve their 
specificity. Particularly, since the 2010 criteria show a loss of specificity relative to the 1987  criteria5,6,10,12. A loss 
that has been quantified at 4% across 12  studies6. The need for the highest specificity is taken very seriously 
because classification criteria are developed to obtain homogeneous groups of patients for  research3,5. A way to 
obtain increased specificity has become possible very  recently14,15. It exploits the concordance of autoantibod-
ies to achieve high specificity, accuracy and reproducibility of the criteria. The concordance in antibody status, 
either positive or negative, is a well-known characteristic of RF and anti-CCP in the patients with RA. In other 
words, the fraction of antibody discordant subjects, subjects showing RF without anti-CCP or anti-CCP without 
RF, is much smaller in the RA patients than in the healthy controls and controls with other  diseases27–30. This 
characteristic extends to the anti-CarP antibodies. In effect, the excess concordance of RF, anti-CCP and anti-
CarP antibodies in the RA patients has been confirmed in a recent compilation of 12  studies24. All the studies 
showed the three antibodies were much more concordant in the RA patients than in the controls, either healthy 
controls, first degree relatives of RA patients, or disease  controls24. This characteristic was exploited by us to 
replace the serological component of the ACR/EULAR 2010 classification criteria by a score based on the con-
cordance of the anti-CarP, RF and anti-CCP autoantibodies. This score led to classify the patients with similar 
accuracy in our  cohort14, and, independently in another large cohort of patients with  EA15. A replication that 
highlights the advantage of a scoring system that does not require antibody concentrations, its reproducibility. 
In effect, antibody concentrations vary between laboratories and it has been shown to limit reproducibility of 
the RA classification  criteria10.
Here, we have evaluated the two best-performing  AAPA18–20. The first part of our analysis did not replicate 
the high sensitivity for seronegative patients previously reported by Studenic et al.20,21. However, the second part 
showed the anti-AcOrn antibodies led to the most accurate classification, significantly better than the 2010 ACR/
EULAR classification criteria, with the concordance scoring system.
Patients and methods
Patients and samples. Patients included in the study comprised the 1062 EA patients used in a previous 
 report16. They had been recruited in the PEARL (Princesa Early Arthritis Register Longitudinal)  study31 at Hos-
pital Universitario La Princesa (from July 2001 to December 2014) and at Hospital Universitario La Paz (from 
January 1993 to December 2013)32, both in Madrid. They presented 2 or more swollen joints for less than a year 
and were naïve for Disease-Modifying Anti-Rheumatic Drugs (DMARD) at the first visit. In addition, they had 
completed 2 years of follow-up and there was available serum from the baseline visit. At the end of the 2-year 
follow-up, these patients were classified according to the 1987 ACR classification criteria for  RA4. This clas-
sification in RA and non-RA was taken as the gold standard for comparison. A choice based on the increase in 
sensitivity of the 1987 criteria at this time relative to the first visit. The EA clinic and the sample collections were 
approved by the La Paz University Hospital Ethics Committee and the Ethics Committee for Clinical Research 
of Hospital Universitario La Princesa (Ref. PI-518). The study was approved by the Autonomous Research Ethics 
Committee of Galicia (Ref. 2014/387 and 2017/514). All participants provided their written informed consent 
and all protocols and methods were conducted according to the relevant guidelines (Declaration of Helsinki, the 
Belmont Report and the Spanish Law of Biomedical Research no. 14/2007).
Determination of autoantibodies. We measured IgG autoantibodies against 2 acetylated peptides 
derived from vimentin, one of them with acetylated lysine (anti-AcLys) and the other with acetylated ornith-
ine (anti-AcOrn) at position 7 of the peptide. The ELISA was performed according to the Orgentec protocol 
described  elsewhere18. No peptides without acetylated amino-acids were assayed given the low frequency of 
reactivity against them in previous studies. Two different lots of the peptides, plates and other reagents were 
provided by Orgentec (Orgentec Diagnostika GmbH, Germany), but they are not commercially available. The 
cut-off for positivity was defined as the  98th percentile of antibody reactivity in the sera of 270 healthy controls 
from Hospital Clínico Universitario de Santiago (Santiago de Compostela, Spain). It corresponded to 64 U/ml 
for anti-AcLys and 55 U/mL for anti-AcOrn antibodies. The inter-assay coefficients of variability across all the 
ELISA plates were 3.8% and 3.3% for the anti-AcLys and anti-AcOrn antibodies using a control showing 159 and 
152 U/mL, respectively. The status of the other autoantibodies (RF, anti-CCP and anti-CarP) was available from 
a previous  study16. Precisely, the anti-CarP antibodies were determined using a homemade ELISA with in vitro 
carbamylated FCS, the IgM-RF was determined by nephelometry, and the anti-CCP antibodies by standardized 
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ELISA. The particular anti-CCP kit was the anti-CCP2 Euro-Diagnostica Immunoscan RA (positive > 50 U/ml) 
for all patients in Hospital Universitario La Paz and until October 2010 in PEARL. Thereafter the QUANTA Lite 
CCP3 IgG and IgA assay of Inova Diagnostics (positive > 40 U/ml) was used in PEARL.
Statistical analysis. Continuous patient variables were compared with the U of Mann–Whitney test or 
t-test according to their distribution, whereas dichotomous variables were compared with 2 × 2 contingency 
tables. Quantile normalization of the optical densities was used to correct for differences between the two anti-
acetylated peptide ELISA lots. Most analyses considered only two statuses for each antibody, positive or negative, 
but other analyses considered three levels following the 2010 ACR/EULAR classification  criteria2. These three 
levels were: negative, positive below 3 times the cut-off value for each antibody, and positive over 3 times the 
cut-off. The cut-offs for anti-CCP and RF antibodies were taken from the manufacturer and the 3 times cut-off 
value was separately calculated for each anti-CCP kit in each EAC. The cut-off for anti-AcLys and anti-AcOrn 
antibodies was calculated as described above whereas that of anti-CarP antibodies has been defined  previously26. 
Concordance between antibody status was measured with the Goodman and Kruskal’s gamma coefficient (γ), 
(ranging from + 1 = perfect concordance to − 1 = complete discordance). In addition, the association between the 
antibodies and RA was assessed with logistic regression accounting for age, sex, the specific EA clinic, and the 
status of other autoantibodies. Other parameters of classification performance were sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood 
ratio (LR−) and the area under (AUC) the receiver operating characteristic (ROC) curves. The sensitivity and 
specificity of different antibodies or antibody combinations were compared with the McNemar’s test for paired 
contingency tables. Also, we assessed the RA classification based on the concordance of the  autoantibodies14. 
For the logistic regression analysis, only the main effects were ascertained. Moreover, the logistic regression fit 
to the data was assessed with the Nagelkerke  R2, and the Akaike’s Information Criterion (AIC). The Nagelkerke 
 R2 estimates the predictive power of the model as a proportional reduction in error variance. The AIC estimates 
the relative amount of information lost by any model. Therefore, the  R2 increases with the predictive power of 
the model, whereas the AIC reaches lower values for the best models. Differences in AIC > 2 between any two 
models are meaningful, whereas differences > 10 are interpreted as rejecting the poorer  model33. Finally, the 
impact of the different serological criteria on the overall classification (serological + non-serological criteria) was 
explored in the patients from PEARL, who featured all the required information. This exploration was under-
taken in two ways. The first consisted of replacing the serological scores in the 2010 ACR/EULAR criteria. The 
second classified the patients with logistic regression that combined the non-serological and serological criteria 
applying cut-offs that were adjusted to obtain a constant sensitivity. The results of these classifications were 
expressed as specificity (true nonRA/observed nonRA patients), sensitivity (true RA/observed RA patients) and 
accuracy ((true nonRA + true RA)/all patients). The statistical tests were performed with R through the Jamovi 
 application34,35 and Statistica version 7.0 (StatSoft, Tulsa, OK) except for the ROC analysis, which was done with 
SPSS version 15.0 (Chicago, USA). Area proportional Venn diagrams were produced with EulerAPE 3.036.
Results
Prevalence of the anti‑acetylated peptides antibodies in the EA patients. The 1062 patients with 
EA were divided at the end of the 2 years of follow-up into 49.9% with RA and 50.1% without RA. This latter 
group included patients with undifferentiated arthritis (20%) and other less common diseases that add up to 
the remaining 30.1%. The diseases in the latter group were spondyloarthritis, Sjögren syndrome, systemic lupus 
erythematosus, psoriatic arthritis, inflammatory bowel disease… The retrospective analysis showed that the RA 
and non-RA patients already differed in several features at the first visit: age, length of the symptoms, disease 
activity, presence of erosions and the prevalence of the autoantibodies (Table 1). In effect, the five antibodies, 
including the two AAPA, were very significantly associated with RA.
To complete the preceding analyses, the association between the presence of the AAPA and RA was assessed 
with logistic regression accounting for other antibodies and variables (Supplementary Table S1 online). This 
analysis showed that the anti-AcLys antibodies were no longer associated when the presence of anti-CCP and 
RF were considered. In contrast, the anti-AcOrn antibodies remained significantly associated when the other 
autoantibodies were considered, even when the anti-CarP antibodies were added. In the most complete analysis 
with four antibodies, the strength of the association with RA went in decreasing order from the anti-CCP anti-
bodies (OR 10.0) to RF (OR 2.9), the anti-AcOrn antibodies (OR 1.6) and the anti-CarP antibodies (OR 1.6). 
The combination of the two AAPA was marginally more associated than the anti-AcOrn antibodies separately 
(Supplementary Table S1 online).
We also explored if the stratification of the AAPA by their levels could add discriminant value. Three levels 
were defined as in the ACR/EULAR 2010 classification criteria: negative and above or below 3 times the cut-off 
of the positive patients (Supplementary Table S2 online). Unlike the RF and anti-CCP antibodies, the high levels 
of the AAPA were not more associated with RA than the low levels. These results excluded the AAPA concentra-
tion strata from RA classification rules.
Relations between the autoantibodies. The two AAPA were strongly concordant in status, both in 
the RA (γ = 0.89, p = 8.9 × 10–70) and non-RA patients (γ = 0.98, p = 1.5 × 10–119). As a consequence, their rela-
tions with RF and the anti-CCP antibodies were similar (Fig. 1). For the anti-AcOrn antibodies, the largest two 
strata of RA patients comprised the triple-positive and the anti-CCP/RF double-positive patients (Fig. 1A). The 
subset of patients positive only for the anti-AcOrn antibodies, which is of particular relevance to increase the 
sensitivity of RA classification, represented only 2.3% of the total (or 9.3% of the RF and anti-CCP seronegative 
RA patients). A completely different distribution was observed in the non-RA patients (Fig. 1B), where the larg-
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Table 1.  Clinical and serological features of the EA patients. a EA patients classified as RA or non-RA 
according to the 1987 ACR classification criteria at 2 years of follow-up. b Features corresponding to the 
first visit are presented. c p values correspond to the comparison of the RA and non-RA patients with the 
chi-squared or t-tests/U of Mann–Whitney test #. d Information was available for < 95% of the patients: ever 
smoker = 92.7%; erosions = 83.1%.
All = 1062 RAa = 530 Non-RA = 532 Pc
Women, n (%)b 818 (77.0) 420 (79.2) 398 (74.8) 0.09
Age, median (IQR ) years 52.0 (40.0–65.2) 54.0 (43.0–67.4) 49.2 (37.0–63.6) 2.5 × 10–05
Delay, median (IQR ) weeks 16.0 (8.0–28.1) 19.9 (11.0–30.7) 12.0 (6.0–26.4) 1.6 × 10–10 #
DAS28, median (IQR ) 4.5 (3.4–5.8) 5.2 (3.9–6.3) 3.9 (2.9–4.9) 1.3 × 10–34
Erosions, n (%)d 93 (10.5) 77 (14.6) 16 (4.5) 1.9 × 10–06
Ever smoker, n (%)d 444 (45.1) 234 (46.0) 210 (44.2) 0.6
RF+, n (%) 444 (41.8) 358 (67.5) 86 (16.2) 1.3 × 10–64
anti-CCP+, n (%) 397 (37.4) 351 (66.2) 46 (8.6) 9.1 × 10–84
anti-CarP+, n (%) 291 (27.4) 222 (41.9) 69 (13.0) 4.4 × 10–26
anti-AcLys+, n (%) 142 (13.4) 111 (21.1) 31 (5.8) 2.9 × 10–13
anti-AcOrn+, n (%) 236 (22.2) 191 (36.1) 45 (8.5) 2.6 × 10–27
AAPA+, n (%) 259 (24.5) 209 (39.7) 50 (9.4) 2.2 × 10–30
Figure 1.  Relations of the AAPA with RF and the anti-CCP antibodies in the EA patients. The relations of the 
anti-AcOrn antibodies are shown in the (A) and (B) plots, whereas the anti-AcLys antibodies are shown in the 
(C) and (D) plots. The (A) and (C) plots represent the RA patients, whereas the (B) and (D) plots show the 
non-RA patients. The percentages are the fraction of the total.
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est subgroup was negative for the three antibodies. They were followed by the positive for unique antibodies: 
RF, anti-AcOrn or anti-CCP. A notably similar pattern of relations was observed with the anti-AcLys antibodies 
in the non-RA patients (Fig. 1D). In contrast, the distribution of the anti-AcLys antibodies in the RA patients 
did not resemble that of the anti-AcOrn antibodies: it was dominated by an enlarged subgroup of anti-CCP/
RF double-positive patients followed by the triple-negative patients and a reduced subgroup of triple-positive 
patients (Fig. 1C). It was notable that the two critical subsets for improving RA classification were less frequent 
in the anti-AcLys than the anti-AcOrn antibodies (Fig. 1A,C): the patients positive only for the AAPA and the 
triple-positive patients.
Diagnostic parameters of the AAPA. A variety of parameters assessing the AAPA contribution to RA 
classification were calculated (Table 2 and Supplementary Table S3 online). The fundamental parameters sen-
sitivity and specificity were compared with the classical antibody combination: positive for “RF or anti-CCP” 
(Table 2). This analysis showed the AAPA were notably less sensitive than the classical antibody combination 
on the whole set of patients. In addition, the AAPA were positive in less than 11% of the anti-CCP− or the anti-
CCP−/RF− patients. In contrast, the AAPA showed high specificity (Table 2). It was higher than the specificity 
of the “RF or anti-CCP” combination and it was preserved in the “seronegative” patients, both anti-CCP− and 
anti-CCP−/RF− patients. This high specificity suggested an improved classification could be obtained with an OR 
combination. The actual testing of the three- and four-antibody combinations showed very modest but signifi-
cant increases in sensitivity (Table 2). The increases were of 1.4% with the anti-AcLys, 2.2% with the anti-AcOrn, 
and 2.5% with the combination of the two AAPA (p < 0.015 for all the comparisons with the “RF or anti-CCP” 
rule). These improvements were associated with a decrease in specificity that was of 3.7% with the anti-AcLys, 
4.9% with the anti-AcOrn, and 5.4% with the AAPA combination (p < 2.5 ×  10–5 for all the comparisons with the 
“RF or anti-CCP” reference). In other words, the benefit–cost ratio of the antibody combinations was 1:2.2 for 
the “RF or anti-CCP or anti-AcOrn antibodies” and the “RF or anti-CCP or anti-AcOrn or anti-AcLys antibod-
ies” rules. This ratio meant that for each new correctly classified RA patient there will be 2.2 non-RA patients 
falsely classified as having RA. In turn, the benefit–cost ratio of the rule with the anti-AcLys antibodies was 1:2.6 
and the recently reported with the anti-CarP antibodies was 1:3.716. These values were not significantly different 
between them. As an alternative, we tested the value of combining the antibodies with the AND operator but 
this approach resulted in a notable decrease in the sensitivity, which is the parameter with the highest need for 
improvement (Supplementary Table S4 online). None of the other analysed parameters (Supplementary Table S3 
online) showed a significant improvement with the AAPA.
Improved serological classification based on antibody concordance. The relations of RF, anti-
CCP and anti-AcOrn antibodies presented above (Fig. 1A,B) suggested their concordance could be useful for RA 
classification. This hypothesis was further supported by the discrimination afforded with the number of positive 
antibodies relative to the serological component of the 2010 ACR/EULAR criteria (Supplementary Table  S5 
online). Therefore, we directly compared the serological component of the 2010 criteria with the antibody con-
cordance in separate logistic regression models (Table 3). In the separate logistic regressions, the highest OR 
(48.7) corresponded to the concordant presence of the three antibodies (RF, anti-CCP and anti-AcOrn antibod-
ies). It was followed by the concordant presence of two antibodies (OR 28.5) and at a similar level the high levels 
of RF or anti-CCP antibodies (OR 25.9). The same order was observed within the logistic model combining the 
two serological criteria (OR 11.4, 7.9 and 4.4, respectively, Table 3). This hierarchy indicates a higher weight of 
the concordance that could lead to better classification than with the 2010 serological component. The improve-
ment was demonstrated with the comparison of the overall performance of the models, which was done with the 
 R2 and AIC parameters. The  R2 is better when it is larger, as it was in the concordance model (0.451) compared 
with the 2010 serological component (0.422). In contrast, the AIC is better when is lower, as in the concordance 
model (1037) relative to the 2010 serological criteria (1067). This latter difference is considered discriminant 
(> 10). A further improvement in performance was obtained with the combined model  (R2 = 45.6%, AIC = 1027). 
Table 2.  Sensitivity and specificity of the AAPA for the RA classification of the EA patients. The antibodies 
were considered in isolation and combinations using the OR operator. a Sensitivity and specificity were 
evaluated in all EA patients and the specified subsets. b na not applicable. c Values already reported on the left 
columns but repeated for easy comparison.
anti-AcLys anti-AcOrn AAPA RF or anti-CCP
RF or anti-CCP or 
anti-AcLys
RF or anti-CCP or 
anti-AcOrn
RF or anti-CCP 
or AAPA
Sensitivity
Alla 21.1 36.1 39.7 75.7 77.1 77.9 78.2
Anti-CCP- 5.6 8.4 9.6 27.9 32.6 34.6 35.4
Anti-CCP-/RF- 6.3 9.3 10.2 Nab 6.3c 9.3c 10.2c
Specificity
All 94.2 91.5 90.6 79.5 75.8 74.6 74.1
Anti-CCP- 95.1 93.4 92.6 87.0 82.9 81.7 81.1
Anti-CCP-/RF- 95.3 93.9 93.1 na 95.3c 93.9 c 93.1c
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In contrast, none of the models based on the concordance with other antibodies, anti-AcLys  (R2 = 44.6%, 
AIC = 1038) or anti-CarP antibodies  (R2 = 44.2%, AIC = 1048), was better than the including anti-AcOrn.
Improved RA classification with the anti‑AcOrn antibodies. The final test to ascertain the clas-
sification consists in combining the serological models with the non-serological components of the 2010 ACR/
EULAR criteria (Table 4). This analysis was only possible in the PEARL cohort (537 EA patients) because of data 
availability. The results showed an improvement in specificity and accuracy with the antibody concordance of 
RF, anti-CCP and anti-AcOrn antibodies. In more detail, the specificity was significantly larger than with the 
2010 criteria (77.6 vs. 72.6%, p = 0.003). This increase was accompanied by a numerically larger sensitivity (80.2 
vs. 78.8%, p = 0.25) and a significantly improved accuracy (79.0 vs. 75.8%, p = 0.002). This improvement was not 
attributable to the specific scoring that was used as it was replicated with the logistic regression model with-
out predefined scores (Table 4; specificities: 79.2 vs. 73.8%, p = 9.5 × 10–6; accuracies: 80.0 vs. 77.1%, p = 0.007). 
Another notable result of these analyses was that the classification incorporating a combination of the serological 
scores (Ccdc. anti-AcOrn + 2010 in Table 4) was not better than the based only on antibody concordance (Ccdc. 
anti-AcOrn in Table 4).
The improvement in RA classification with the anti-AcOrn antibodies was significantly larger than the 
obtained with the anti-CarP antibodies, which we had recently  reported16, and that is shown here for direct 
comparison (Table 4; scores specificity: 77.6 vs. 75.3%, p = 0.03, and accuracy: 79.0 vs. 77.1%, p = 0.01; logistic 
regression specificity: 79.2 vs. 75.7%, p = 0.002, and accuracy: 80.0 vs. 77.8%, p = 0.01).
Discussion
We have identified the anti-AcOrn as RA autoantibodies that in our patients improved the specificity and accu-
racy of the RA classification and freed it from the reliance on antibody levels. The significant improvement was 
obtained with one of the two explored approaches: the use of a scoring system based on the antibody concord-
ance. In this approach, the anti-AcOrn concordance with RF and anti-CCP antibodies was superior to that of 
the anti-AcLys and anti-CarP antibodies. The improvements over the 2010 ACR/EULAR criteria were significant 
in specificity and accuracy, and not significant in sensitivity. These improvements should stimulate replication 
and further analysis. Only after replication and expert consensus, a recommendation for changes in the RA 
Table 3.  Comparison of logistic regression models for RA classification based on the serological 2010 criteria, 
the antibody concordance, and their combination. a The serological component of the 2010 ACR/EULAR 
RA classification criteria, the concordance (Ccdc.) of RF, anti-CCP and anti-AcOrn autoantibodies, and 
their combination (2010 + Ccdc.) b OR and their 95% confidence intervals. c This stratum did not contribute 
significantly to RA classification.
Stratum
2010 ACR/EULARa Ccdc. anti-AcOrn 2010 + Ccdc. anti-AcOrn
OR (95% CI)b OR (95% CI) OR (95% CI)
3 25.9 (17.9–37.6) – 4.4 (1.9–10.4)
2 2.5 (1.6–3.8) – 1.2 (0.5–2.6)c
3Ab – 48.7 (25.5–93.0) 11.4 (4.0–32.9)
2Ab – 28.5 (17.1–47.4) 7.9 (3.0–20.4)
1Ab – 2.7 (1.9–3.9) 1.6 (0.8–3.2)c
Table 4.  Performance of the classification criteria for RA with different serological components. a 2010 ACR/
EULAR = RF or anti-CCP antibodies as in the 2010 ACR/EULAR classification criteria; Ccdc. anti-AcOrn 
concordant for RF, anti-CCP and anti-AcOrn antibodies; Ccdc. anti-CarP concordant for RF, anti-CCP and 
anti-CarP antibodies. b Scores were as in the 2010 ACR/EULAR criteria; as in Regueiro et al.16 depending on 
the number of concordant antibodies: 5 for 3, 3 for 2, and 1 for 1 antibodies; or combining the two criteria as: 
5 for 3 or 2 antibodies with high levels, 3 for 3 or 2 antibodies with low levels, and 1 for 1 antibody irrespective 
of the levels. c Classification was done with logistic regression including each component: joint symptoms, 
serology, symptom duration, and acute-phase reactants with the cut-off adjusted to obtain 80% sensitivity. This 
analysis is slightly different from the reported in Regueiro et al. where the three non-serological factors were 
grouped.
Serological  componenta
Scoresb Logistic  regressionc
Specificity Sensitivity Accuracy Specificity Accuracy
2010 ACR/EULAR 72.6 78.8 75.8 73.8 77.1
Ccdc. anti-AcOrn 77.6 80.2 79.0 79.2 80.0
Ccdc. anti-AcOrn + 2010 77.6 81.3 79.5 80.3 80.6
Ccdc. anti-CarP 75.3 78.8 77.1 75.7 77.8
Ccdc. anti-CarP + 2010 76.4 80.6 78.8 79.5 80.0
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classification could be envisaged. The other explored approach, aimed to use the anti-AcOrn as a biomarker for 
the RF and anti-CCP “seronegative” patients, did not result in meaningful improvements.
Other reports have already signalled the anti-AcOrn antibodies outperform several other AAPA as RA bio-
markers although they did not explore RA  classification18–22. The combination of anti-AcOrn with anti-AcLys 
did not result in significant improvements in sensitivity, probably because of the high concordance between 
them. In this regard, it is worth mentioning the AAPA sensitivity for the “seronegative” RA patients was much 
lower than the observed in two previous  reports20,21. These two reports are only available as meeting abstracts, 
a circumstance that limits the search for possible causes of the discrepant results. In contrast, our results are in 
line with the 13.2% anti-CCP negative patients that were positive for the anti-AcLys antibodies in the unique 
additional article with this  information18.
The low sensitivity in the RF and anti-CCP “seronegative” patients indicates the AAPA will not be of utility 
to improve the classification of this subset of  patients7, 8,11–13. Unfortunately, this seems to be the common out-
come with the autoantibodies given their concordant presence in the RA  patients16–18. Even, the concordance 
may reflect shared underlying pathways, as suggested by the recent work indicating that smoking predisposes 
primarily to RA with multiple  autoantibodies37–39.
Independently of its causes, the concordance of antibodies is a defining characteristic of RA  patients16–18,24,27–30, 
which could be exploited to improve RA classification in another  way14,15. The improvement exploits the better 
specificity of the concordant presence of two or three antibodies relative to any of them in isolation. An observa-
tion that was evident in the 12 studies compiled in Verheul et al.24. Therefore, we have proposed a scoring system 
that gives a higher weight to the serologic component than the 2010 ACR/EULAR criteria (5 points for the top 
serological score of a total of 6 needed)14. This approach has led to improvements in the classification with the 
anti-CarP antibodies. Improvements that were independently replicated in the Leiden EA  cohort15. Here, a 
similar pattern of concordance was found with the anti-AcOrn antibodies in place of the anti-CarP antibodies. 
This concordance criteria with anti-AcOrn led to higher specificity and accuracy than the 2010 ACR/EULAR 
criteria and higher also than the obtained with the anti-CarP antibodies. The improvements obtained with the 
anti-AcOrn concordance scores over the 2010 ACR/EULAR criteria were of significant magnitude (specificity 
5% and accuracy 4.2%). The relevance of the improvement is revealed considering that classification criteria are 
a tool to identify homogeneous groups of patients for  research2–5. An objective that calls for the highest possible 
specificity to permit replication, comparison and transference of the research results. Our results suggest it will be 
possible to retain the increased sensitivity of the 2010 criteria for early RA without paying the price of decreased 
specificity relative to the 1987 criteria (a loss quantified at 4%)5,6.
The independence form antibody levels is an advantage of the anti-AcOrn over the anti-CarP antibodies 
whose concordance scores need to be combined with scores based on the RF and anti-CCP levels to reach similar 
specificity and accuracy. The independence from antibody levels is also an advantage over the 2010 ACR/EULAR 
criteria and another previously explored modification on the  criteria10. An important component of the latter 
was requiring high levels of RF to increase specificity. However, high levels of RF were less reproducible than RF 
positivity between the three analysed cohorts leading the authors to propose dropping RF levels from the clas-
sification  criteria10. The same report showed that the distinction in RF levels added little to classification. This 
could be explained by the correlation between high RF levels and anti-CCP presence observed in our patients 
(Supplementary Table S6) and in other sets of RA  patients38–40. Therefore, the lack of reliance on the RF and 
anti-CCP levels will permit increasing reproducibility of the RA classification based on anti-AcOrn concordance 
without losing accuracy.
Another aspect that could affect the reproducibility of the findings pertains to differences in the patient 
populations. In this respect, the frequency of smokers was lower in our patients than in some other European 
EA  cohorts37–39. However, we did not find that smoking alters the association of antibody concordance with the 
RA classification. In effect, the OR for RA in the concordant patients for 3, or 2 antibodies (RF, anti-CCP or 
anti-AcOrn) were very similar in ever smokers and the global set of patients (46.8 vs. 48.7, for 3 antibodies and 
30.3 vs. 28.3 for 2 antibodies, respectively).
It is important to highlight that our results do not imply the anti-AcOrn antibodies are involved in the RA 
pathogenesis. This is a question that should be solved with other types of experiments. Also, additional experi-
ments will be needed to identify the natural antigen recognized by the anti-AcOrn antibodies because the peptide 
used in our assay is artificial in several  respects18,19. This field is at a stage that could be similar to the experienced 
by the anti-citrullinated protein antibodies some decades  ago41,42. They were first detected as antibodies against 
cutaneous proteins, keratin or epidermal  filaggrin43,44. Only after years of study, it was discovered that these 
antibodies were targeting citrullinated proteins that are present in the inflamed joints as vimentin, fibrinogen, 
enolase or  histones41,42. It is encouraging that the first natural acetylated protein autoantigens, acetylated his-
tones, have already been identified as RA autoantigens with a possible role in pathogenesis via antibody-NETosis 
 interactions45. Whereas these questions are clarified, the anti-AcOrn antibodies can be used as biomarkers 
because they reveal a fraction of the spectrum of antibodies not uncovered with the other autoantibodies stud-
ied here. This extreme was evidenced in the logistic regression analysis including RF, anti-CCP and anti-CarP 
antibodies in addition to the anti-AcOrn antibodies. These same arguments show that the improvements we 
have found are not undermined by the recent studies demonstrating various levels of cross-reactivity between 
RA  autoantibodies46,47.
A limitation of this study is the variation between the two lots of the AAPA assays we used that required 
normalization and reestablishment of the threshold for positivity. We do not know if this problem was punctual 
or has happened with additional reagent lots. In favour of the punctual problem is the use of the AAPA assays by 
other researchers without reporting any technical  limitation18–23. It should be noted that caution and appropriate 
controls are always needed with this type of research assays that are not commercially available, nor approved for 
clinical use. Also, replication of the findings on other sample collections is required to be confident in the results. 
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This need for prudence applies particularly to the ranking of the anti-AcOrn antibodies as more informative 
than the anti-CarP antibodies because the differences in performance were small or non-significant. Also, it will 
be important to analyse EA cohorts including patients with any joint swelling, in place of the two swollen joints 
required in our EA cohorts. Another limitation is the possible error in the assessment of the value of the AAPA 
introduced by the presence of RF in the 1987 RA classification criteria that we used after 2-years of follow-up. The 
weight of RF in that criteria is lower than in the 2010  criteria4, but still, it was unclear if it was biasing the results. 
To assess this possibility, we compared the anti-AcOrn performance in the anti-CCP− and the  RF− patients. A 
significant bias due to the presence of RF in the 1987 criteria should result in increased sensitivity for the anti-
CCP− patients. Reassuringly, the contrary result was found: the sensitivity for RA patients was 8.4% and 17.4% 
for the anti-CCP− and  RF− patients, respectively. Finally, implementation of the anti-AcOrn antibodies will 
require an additional laboratory test, but the added cost and labour will not be considered too cumbersome in 
the research setting that is the primary place of classification criteria.
In summary, the anti-AcOrn antibodies showed the best potential for improving the accuracy of the current 
RA classification among the analysed antibodies. This potential was demonstrated with a scoring system based 
on antibody concordance. The improvement affected specificity and accuracy and made redundant the stratifica-
tion according to antibody concentrations. Regarding sensitivity, our analysis did not replicate the reported high 
sensitivity of the AAPA in the “seronegative” RA patients. In consequence, they were not as useful for improving 
the sensitivity of RA classification as suggested in previous reports. Although encouraging, our results should be 
taken with prudence until confirmed in other cohorts, particularly concerning the relative benefits achievable 
with anti-AcOrn and anti-CarP antibodies.
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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